Personalis Inc
NASDAQ:PSNL

Watchlist Manager
Personalis Inc Logo
Personalis Inc
NASDAQ:PSNL
Watchlist
Price: 3.47 USD 2.66% Market Closed
Market Cap: 245.2m USD
Have any thoughts about
Personalis Inc?
Write Note

Personalis Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Personalis Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Personalis Inc
NASDAQ:PSNL
Current Portion of Long-Term Debt
$1.2m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Current Portion of Long-Term Debt
$4.1B
CAGR 3-Years
501%
CAGR 5-Years
44%
CAGR 10-Years
3%
Danaher Corp
NYSE:DHR
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
456%
CAGR 5-Years
2%
CAGR 10-Years
33%
Mettler-Toledo International Inc
NYSE:MTD
Current Portion of Long-Term Debt
$185.8m
CAGR 3-Years
51%
CAGR 5-Years
31%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
137%
CAGR 5-Years
66%
CAGR 10-Years
50%
No Stocks Found

Personalis Inc
Glance View

Market Cap
245.1m USD
Industry
Life Sciences Tools & Services

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

PSNL Intrinsic Value
1.91 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Personalis Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.2m USD

Based on the financial report for Sep 30, 2024, Personalis Inc's Current Portion of Long-Term Debt amounts to 1.2m USD.

What is Personalis Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-12%

Over the last year, the Current Portion of Long-Term Debt growth was 209%. The average annual Current Portion of Long-Term Debt growth rates for Personalis Inc have been -12% over the past three years .

Back to Top